Product logins

Find logins to all Clarivate products below.


Postoperative Pain | Current Treatment: Physician Insights | US | 2019

A variety of analgesic products are available to specialists managing postoperative pain in the United States, although the majority of these medicines are available as inexpensive generics. Physicians generally rely on multimodal therapy to manage acute postoperative pain, layering drugs in different analgesic classes (e.g., an NSAID / acetaminophen and an opioid), in an attempt to minimize side effects and reduce opioid consumption. Branded products, such as AcelRx’s Dsuvia, Mallinckrodt’s Ofirmev, and Pacira’s Exparel, face market uptake obstacles including hospital adoption and reimbursement constraints. Given the shifting trends in the management of postoperative pain, understanding the treatment algorithm and prescribing drivers is important for marketers of current branded products, as well as developers of emerging therapies.

QUESTIONS ANSWERED

  •  Which drug classes and agents are used most often for postoperative pain, and in which stages of treatment (intraoperative, postoperative, at discharge) are they administered / prescribed?
  • Which drug formulations are most popular at the different stages of treatment, and which physician type (surgical specialist or anesthesiologist) is most involved in prescribing / administering at each stage?
  • How do physicians characterize recent changes in their treatment of postoperative pain, and what changes to current usage do they expect within the next year?
  • What drives physicians to prescribe / administer select branded therapies, and what are the key obstacles holding them back from using these products?

GEOGRAPHY

 United States

PRIMARY RESEARCH

Survey of 50 anesthesiologists, 41 surgical specialists, and 11 orthopedic surgeons.

KEY DRUGS COVERED

Dsuvia, Nucynta IR / ER, Sprix, Caldolor, Ofirmev, Exparel, generic oral and parenteral opioids, NSAIDs / acetaminophen, and local anesthetics.

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…